NASDAQ:ATRC AtriCure (ATRC) Stock Price, News & Analysis → Did you make $29,000 two days with AI options trades? (From Prosper Trading Academy) (Ad) Free ATRC Stock Alerts $30.42 +0.28 (+0.93%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$29.61▼$30.5850-Day Range$28.21▼$37.7852-Week Range$27.92▼$59.61Volume542,164 shsAverage Volume653,468 shsMarket Capitalization$1.47 billionP/E RatioN/ADividend YieldN/APrice Target$55.57 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get AtriCure alerts: Email Address AtriCure MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside82.7% Upside$55.57 Price TargetShort InterestBearish6.14% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.14Based on 7 Articles This WeekInsider TradingSelling Shares$423,212 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.71) to ($0.47) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.86 out of 5 starsMedical Sector662nd out of 938 stocksSurgical & Medical Instruments Industry66th out of 94 stocks 3.5 Analyst's Opinion Consensus RatingAtriCure has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $55.57, AtriCure has a forecasted upside of 82.7% from its current price of $30.42.Amount of Analyst CoverageAtriCure has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.14% of the outstanding shares of AtriCure have been sold short.Short Interest Ratio / Days to CoverAtriCure has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in AtriCure has recently increased by 25.32%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAtriCure does not currently pay a dividend.Dividend GrowthAtriCure does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ATRC. Previous Next 2.3 News and Social Media Coverage News SentimentAtriCure has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for AtriCure this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for ATRC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows7 people have added AtriCure to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AtriCure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $423,212.00 in company stock.Percentage Held by InsidersOnly 3.00% of the stock of AtriCure is held by insiders.Percentage Held by Institutions99.11% of the stock of AtriCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for AtriCure are expected to grow in the coming year, from ($0.71) to ($0.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AtriCure is -46.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AtriCure is -46.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtriCure has a P/B Ratio of 3.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> About AtriCure Stock (NASDAQ:ATRC)AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.Read More ATRC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATRC Stock News HeadlinesMarch 21, 2024 | insidertrades.comAtriCure, Inc. (NASDAQ:ATRC) Insider Sells $60,621.60 in StockMarch 17, 2024 | insidertrades.comKarl S. Dahlquist Sells 8,231 Shares of AtriCure, Inc. (NASDAQ:ATRC) StockMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 15, 2024 | insidertrades.comAtriCure, Inc. (NASDAQ:ATRC) Insider Justin J. Noznesky Sells 1,500 SharesMarch 28, 2024 | ca.finance.yahoo.comATRC May 2024 30.000 callMarch 27, 2024 | americanbankingnews.comAtriCure (NASDAQ:ATRC) Downgraded by StockNews.comMarch 26, 2024 | finance.yahoo.comAtriCure to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceMarch 24, 2024 | americanbankingnews.comAtriCure (NASDAQ:ATRC) Reaches New 12-Month Low at $28.21March 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 22, 2024 | finance.yahoo.comAtriCure (ATRC) Declined due to Concerns Over Anti-Obesity DrugMarch 21, 2024 | americanbankingnews.comAtriCure (NASDAQ:ATRC) Trading Down 3.8% Following Insider SellingMarch 21, 2024 | americanbankingnews.comStockNews.com Upgrades AtriCure (NASDAQ:ATRC) to HoldMarch 16, 2024 | finance.yahoo.comATRC Apr 2024 22.500 putMarch 10, 2024 | finanznachrichten.deSeoul Robotics Explores Partnership in Industrial Autonomous Driving R&D with UAE's Advanced Technology Research Council (ATRC)March 7, 2024 | finance.yahoo.comChief Legal Officer Karl Dahlquist Sells 8,231 Shares of AtriCure Inc (ATRC)February 28, 2024 | finance.yahoo.comAtriCure (ATRC) Fell on Competitor ActionFebruary 17, 2024 | finance.yahoo.comAtriCure Full Year 2023 Earnings: EPS Beats ExpectationsFebruary 16, 2024 | realmoney.thestreet.comAtriCure price target raised by $1 at UBS, here's whyFebruary 16, 2024 | markets.businessinsider.comAtricure’s Strong Growth and Market Position Justify Buy Rating and $65 Target PriceFebruary 16, 2024 | finance.yahoo.comAtriCure, Inc. (NASDAQ:ATRC) Q4 2023 Earnings Call TranscriptFebruary 16, 2024 | markets.businessinsider.comCracking The Code: Understanding Analyst Reviews For AtriCureFebruary 15, 2024 | benzinga.comRecap: AtriCure Q4 EarningsFebruary 15, 2024 | msn.comHere's What Key Metrics Tell Us About AtriCure (ATRC) Q4 EarningsFebruary 15, 2024 | finance.yahoo.comAtriCure Inc (ATRC) Reports Strong Revenue Growth in Q4 and Full Year 2023February 15, 2024 | businesswire.comAtriCure Reports Fourth Quarter 2023 and Full Year 2023 Financial ResultsFebruary 14, 2024 | msn.comAtriCure Q4 2023 Earnings PreviewFebruary 14, 2024 | finanznachrichten.deAdvanced Technology Research Council: Serbia Signs with UAE's ATRC to Encourage Use of Falcon AI Models at WGS 2024See More Headlines Receive ATRC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/15/2024Today3/29/2024Next Earnings (Estimated)5/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:ATRC CUSIP04963C20 CIK1323885 Webwww.atricure.com Phone(513) 755-4100Fax513-755-4567Employees1,200Year Founded2000Price Target and Rating Average Stock Price Target$55.57 High Stock Price Target$68.00 Low Stock Price Target$42.00 Potential Upside/Downside+82.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,440,000.00 Net Margins-7.62% Pretax Margin-7.48% Return on Equity-7.55% Return on Assets-5.83% Debt Debt-to-Equity Ratio0.15 Current Ratio3.57 Quick Ratio2.66 Sales & Book Value Annual Sales$399.24 million Price / Sales3.69 Cash FlowN/A Price / Cash FlowN/A Book Value$9.84 per share Price / Book3.09Miscellaneous Outstanding Shares48,380,000Free Float46,924,000Market Cap$1.47 billion OptionableOptionable Beta1.39 Social Links The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Michael H. Carrel (Age 53)CEO, President & Director Comp: $1.62MMs. Angela L. Wirick CPA (Age 46)Chief Financial Officer Comp: $668.62kMr. Douglas J. Seith (Age 58)Chief Operating Officer Comp: $989.17kMr. Justin J. Noznesky (Age 46)Chief Marketing & Strategy Officer Comp: $644.73kMs. Deborah Yount (Age 58)Chief Human Resources Officer Comp: $498.36kMr. Salvatore Privitera J.D. (Age 57)Chief Technical Officer Comp: $471.15kDr. Vinayak Doraiswamy Ph.D. (Age 52)Chief Scientific Officer Comp: $777.66kMr. Karl S. Dahlquist CCEP (Age 54)J.D., Chief Legal Officer Valerie Storch-WillhausVice President of Corporate Marketing & CommunicationsMore ExecutivesKey CompetitorsAlphatecNASDAQ:ATECCardiovascular SystemsNASDAQ:CSIINuVasiveNASDAQ:NUVAOrthofix MedicalNASDAQ:OFIXSurmodicsNASDAQ:SRDXView All CompetitorsInsiders & InstitutionsKarl S DahlquistSold 1,885 sharesTotal: $60,621.60 ($32.16/share)Justin J NozneskySold 1,500 sharesTotal: $55,080.00 ($36.72/share)Vanguard Group Inc.Bought 76,146 shares on 3/11/2024Ownership: 10.015%Wellington Management Group LLPBought 95,824 shares on 3/5/2024Ownership: 2.794%Karl S DahlquistSold 8,231 sharesTotal: $307,510.16 ($37.36/share)View All Insider TransactionsView All Institutional Transactions ATRC Stock Analysis - Frequently Asked Questions Should I buy or sell AtriCure stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ATRC shares. View ATRC analyst ratings or view top-rated stocks. What is AtriCure's stock price target for 2024? 5 brokers have issued 12 month target prices for AtriCure's shares. Their ATRC share price targets range from $42.00 to $68.00. On average, they anticipate the company's stock price to reach $55.57 in the next year. This suggests a possible upside of 82.7% from the stock's current price. View analysts price targets for ATRC or view top-rated stocks among Wall Street analysts. How have ATRC shares performed in 2024? AtriCure's stock was trading at $35.69 at the beginning of the year. Since then, ATRC shares have decreased by 14.8% and is now trading at $30.42. View the best growth stocks for 2024 here. Are investors shorting AtriCure? AtriCure saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 2,970,000 shares, an increase of 25.3% from the February 29th total of 2,370,000 shares. Based on an average daily volume of 618,100 shares, the days-to-cover ratio is currently 4.8 days. View AtriCure's Short Interest. When is AtriCure's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our ATRC earnings forecast. How were AtriCure's earnings last quarter? AtriCure, Inc. (NASDAQ:ATRC) announced its earnings results on Thursday, February, 15th. The medical device company reported ($0.21) EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.01. The medical device company earned $106.50 million during the quarter, compared to the consensus estimate of $103.68 million. AtriCure had a negative trailing twelve-month return on equity of 7.55% and a negative net margin of 7.62%. The company's quarterly revenue was up 21.0% on a year-over-year basis. During the same period last year, the firm earned ($0.09) EPS. What ETFs hold AtriCure's stock? ETFs with the largest weight of AtriCure (NASDAQ:ATRC) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), Nuveen Small Cap Select ETF (NSCS), Simplify Health Care ETF (PINK), Harbor Corporate Culture Small Cap ETF (HAPS), Principal Healthcare Innovators ETF (BTEC) and Invesco Nasdaq Future Gen 200 ETF (QQQS).iShares U.S. Medical Devices ETF (IHI). What guidance has AtriCure issued on next quarter's earnings? AtriCure issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of -0.820--0.740 for the period, compared to the consensus EPS estimate of -0.690. The company issued revenue guidance of $459.0 million-$466.0 million, compared to the consensus revenue estimate of $455.9 million. What is Michael Carrel's approval rating as AtriCure's CEO? 38 employees have rated AtriCure Chief Executive Officer Michael Carrel on Glassdoor.com. Michael Carrel has an approval rating of 100% among the company's employees. This puts Michael Carrel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at AtriCure to a friend. What other stocks do shareholders of AtriCure own? Based on aggregate information from My MarketBeat watchlists, some companies that other AtriCure investors own include AbbVie (ABBV), Gilead Sciences (GILD), Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Enterprise Products Partners (EPD), Abbott Laboratories (ABT), Neurocrine Biosciences (NBIX), NVIDIA (NVDA), Pfizer (PFE) and Sarepta Therapeutics (SRPT). Who are AtriCure's major shareholders? AtriCure's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (10.05%), Vanguard Group Inc. (10.01%), First Light Asset Management LLC (2.85%), Wellington Management Group LLP (2.79%), Nuveen Asset Management LLC (2.16%) and Dimensional Fund Advisors LP (2.11%). Insiders that own company stock include Angela L Wirick, Angela L Wirick, David D Jr Grumhaus, Douglas J Seith, Justin J Noznesky, Karen Prange, Karl S Dahlquist, Maggie Yuen, Mark A Collar, Mark A Collar, Regina E Groves, Salvatore Privitera, Scott William Drake, Sven Wehrwein, Tonya Austin and Vinayak Doraiswamy. View institutional ownership trends. How do I buy shares of AtriCure? Shares of ATRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does AtriCure have any subsidiaries? The following companies are subsidiares of AtriCure: SentreHEART.Read More This page (NASDAQ:ATRC) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AtriCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.